Panacea Biotec Ltd has plans to forays into oncology segment to provide treatment for breast cancer, brain tumour, ovarian cancer, pancreatic cancer, prostrate cancer and colorectal cancer. The company plans to launch seven anti-cancer products in the next eight weeks. These drugs will be manufactured by a Mumbai based company to be sold under the brand name of the company.

"Oncotrust" would be the new strategic business unit (SBU) of the company with the total strength of 50 sales specialists on oncology who would be responsible for marketing the drugs. The aim is to register sales volumes of Rs 15-20 crore in oncology chemotherapy segment in the next three years.

The company feels that it would be able to launch novel drug delivery based anti-cancer drug in next 2-3 year period.

"We plan to develop novel and innovative drug delivery systems (NDDS) of the existing anti-cancer molecule. The new research based drug development will take 2-3 years as we need to develop an effective distribution chain and occupy a significant market share in oncology drugs." says, Rajesh Jain, joint managing director of the company.

The company also plans to launch its Injectable Polio Vaccine (IPV) in next three months in the private market and would gradually increase the market share after post polio eradication programme of Govt. of India.